Abstracts of the 10 th International Conference on Cachexia, Sarcopenia and Muscle Wasting, Rome, Italy, 8‐10 December 2017 (Part 2)

s of the 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting, Rome, Italy, 8-10 December 2017 (Part 2) 1–07 Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF) Amir Emami, Masakazu Saitoh, Miroslava Valentova, Anja Sandek, Ruben Evertz, Nicole Ebner, Goran Loncar, Jochen Springer, Wolfram Doehner, Mitja Lainscak, Gerd Hasenfuß, Stefan D. Anker & Stephan von Haehling Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany, Cardiology Department, Clinical Hospital Zvezdara, Belgrade, Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, Center for Stroke Research Berlin, Charite University Medical School, Germany, Division of Cardiology, General Hospital Murska Sobota, Slovenia, Faculty of Medicine, University of Ljubljana, Slovenia, Division of Cardiology and Metabolism – Heart Failure, Cachexia & Sarcopenia, Department of Cardiology, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany, Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany Objectives: The aim of the present study was to compare the functional impact of changes in body composition as exemplified by heart failure (HF) patients who have cachexia and/or sarcopenia with patients without body wasting. Methods: We prospectively enrolled 207 ambulatory male patients with clinically stable chronic HF who were subgrouped into four groups; (I) patients with sarcopenia without cachexia (sarcopenic HF group), (II) patients with cachexia without sarcopenia (cachectic HF group), (III) patients with cachexia and sarcopenia (sarcopenic cachexia group), and (IV) patients with neither type of wasting (no wasting group). Results: Cachexia was present in 39 (18.8%) of 207 Patients, 14 of whom also fulfilled the characteristics of sarcopenia (sarcopenic cachexia group, 6.7%), whereas 25 did not (cachectic HF group, 12.1%). Sarcopenia without cachexia was present in 30 patients (sarcopenic HF group, 14.4%). Handgrip strength, peak VO2, distance walked in the 6-MWT, SPPB score, and EQ-5D index score results were lowest in the sarcopenic cachexia group, with significant differences compared to the no wasting group (all p < 0.05). Besides, the sarcopenic cachexia group had the lowest values in quadriceps strength in comparison to the other three groups (all p < 0.05). Likewise, the sarcopenic HF group showed lower handgrip strength, quadriceps strength, 6MWT, peak VO2, SPPB score and EQ-5D index score results, with significant differences compared to the no wasting group (all p < 0.05). Haemoglobin and IL-6 levels were significantly reduced in the sarcopenic cachexia group, as compared with the no wasting group (both p < 0.05). Conclusions: Losing muscle with or without weight loss appears to have a more pronounced role than weight loss alone, in decreasing functional capacity and QOL among male patients with chronic HF. 1–10 Serial changes in fat, muscle, and bone mass in patients with repeat hospitalization due to worsening heart failure Masaaki Konishi, Eiichi Akiyama, Yasushi Matsuzawa, Nobuhiko Maejima, Noriaki Iwahashi, Kiyoshi Hibi, Masami Kosuge, Kazuo Kimura & Kouichi Tamura Yokohama City University Medical Center, Yokohama, Japan Introduction: Loss of body weight in patients with heart failure (HF) is known as cachexia and associated with poor prognosis. However, there is a paucity of data regarding changes in body composition, namely, fat, muscle, and bone mass. Methods: We retrospectively analysed 32 consecutive patients with heart failure (56% men, left ventricular ejection fraction(LVEF) 41 + 14%, NYHA2.0 + 0.5), who experienced re-hospitalization due to worsening HF and had two or more results in dual-energy X-ray absorptiometry (DXA). To minimize influences by excess fluid in body, DXA was measured at stable state after decongestion therapy. Results: Twenty-two (69%) patients had an ischemic aetiology and 13 (41%) was categorized as heart failure with preserved LVEF (LVEF > =50). Median interval between the two measurements of DXA was 415 (IQR: 263, 763) days. In the first measurement, low muscle mass defined by the Asian Working Group for Sarcopenia (i.e., <7.0 kg/m2 in men and <5.4 kg/m2 in women) was ABSTRACTS © 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 183–212 Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12284 This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. observed in 72% of patients. During follow-up period, 69%, 72%, 56%, and 88% of patients experienced weight loss, fat loss, appendicular skeletal muscle loss, and bone loss, defined as any loss of body weight or each body component, respectively. Weight loss was correlated with fat loss (r = 0.77, p < 0.001) and appendicular skeletal muscle loss (r = 0.35, p = 0.047), but not with bone loss (r = 0.08, p = 0.67). Eleven patients with longer history of HF (>5 years) showed greater weight loss than 21 patients with shorter history ( 6.5 + 5.7 vs 0.4 + 8.0%, p = 0.03) whereas none of age, LVEF, and biomarkers (serum albumin, creatinine, lymphocyte count, C-reacting protein, B-type natriuretic peptide) could not predict weight loss, fat loss, and skeletal muscle loss. Conclusions:Weight loss was frequently observed in patients with heart failure requiring repeat hospitalization. Gain and loss of body weight was strongly associated with changes in fat mass in these patients. 1–12 Phase angle measured by bioelectrical impedance analysis in monitoring body composition changes related to treatment and to parenteral nutrition in patients irradiated due of HNC Teresa Małecka-Massalska, Paweł Gołębiowski, Radosław Mlak, Tomasz Powrózek, Monika Prendecka, Anna Brzozowska & Maria Mazurkiewicz Department of Human Physiology, Medical University of Lublin, Radziwiłłowska 11 Street, 20–080, Lublin, Poland, Department of Oncology, Medical University of Lublin, Jaczewskiego 7 Street, 20–090, Lublin, Poland Introduction: Every year, over 600 thousands new cases of Head and Neck Cancer (HNC) are diagnosed. Progressive weight loss and malnutrition are generally found in those patients, especially under treatment (surgery, radiotherapy [RTH], chemotherapy [CTH]) conditions. Nutritional deficiencies have a significant influence on mortality and quality of life in patients with HNC. Bioelectrical impedance phase angle (PA) obtained by bioelectrical impedance analysis (BIA), as a measurable indicator of the body condition at the cellular level, is an alternative parameter to laboratory and anthropometric methods to measure and monitor nutritional status of patients with cancer. The aim of the study was to monitor the changes of PA in adult patients with HNC before each RTH cycle classified as well-nourished, moderately malnourished and severely malnourished according to the SGA scale and the effect of nutritional intervention on the value of PA. Methods: HNC patients were included in the study (n = 30, men, stages: I-IV). All participants were irradiated using IMRT technique (doses: 50-70Gy). Baseline assessment included: demographic, tumour related, nutritional and clinical evaluation as well as laboratory tests (albumin, prealbumin, transferrin, total protein), subjective global assessment (SGA) and PA measured by BIA at 4 frequencies (5/50/100/ 200 kHz) before each RTH cycle. Results: Significantly higher values of PA (50 kHz) have been found in SGA C patients when compared to those SGA A or B, before 6-th (5.48 vs 4.45; p = 0.0418) and 7th cycle of RTH (5.56 vs 4.37; p = 0.0095). In patients treated with parenteral nutrition significantly higher values of PA (50 kHz) measured before 4-th (5.72 vs 4.25; p = 0.0124) and 5-th (5.48 vs 4.38; p = 0.0411) cycle of RTH were found. Conclusions: Our results have shown potential usefulness of PA measured by BIA in monitoring body composition changes related to treatment and to parenteral nutrition in patients irradiated due of HNC. 2–06 Anti-sarcopenic effect suggested by combination of ARB and statin in patients with cardiovascular disease Haruhito Harada, Ryo Shibata, Kazunori Yamaji, Hiroshi Niiyama, Atsushi Katoh & Hisashi Kai Department of Cardiology, Kurume University Medical Center, Kurume, Japan Introduction: Reduction of skeletal muscle mass is the most important component on diagnosis of sarcopenia. Aging and chronic heart failure due to cardiovascular diseases (CVDs) accelerates reduction of skeletal muscle. We previously reported the possibility of statin to treat sarcopenia with CVD. On the other hand, some angiotensin receptor blockers (ARBs), such as telmisartan and irbesartan, induce the activation of PPARγ and the increase of adiponectin, which are known to promote muscle performance and protect skeletal muscle against inflammation and injury. The purpose of this study was to assess the effectiveness of statin and ARB for an anti-sarcopenic effect in patients with CVD. Methods: Study design was a single center retrospective cross-sectional analysis. 670 in-patients with CVD were divided into four groups including patients taking neither stain nor ARB (control), statin alone, ARB alone and both ARB and stain (ARB/statin) for more than 4 weeks. Skeletal muscle volume was assessed by bioelectrical impedance assay. Skeletal muscle index (SMI) and other variables were statistically compared among four groups. Results: No significance in SMI was found in statin and ARB groups compared with control group. However, SMI was significantl